Flag of the European Union EU Clinical Trials Register Help

Clinical trials for erlotinib

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44352   clinical trials with a EudraCT protocol, of which   7379   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    228 result(s) found for: erlotinib. Displaying page 2 of 12.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2010-020394-17 Sponsor Protocol Number: ARD11585(MM-121-01-101) Start Date*: 2011-10-18
    Sponsor Name:MERRIMACK PHARMACEUTICALS
    Full Title: A Phase 1-2 trial of MM-121 in Combination with Erlotinib in Three Groups of Patients with Non-Small Cell Lung Cancer
    Medical condition: Patients with Non-Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-001168-35 Sponsor Protocol Number: A4021018 Start Date*: 2008-07-09
    Sponsor Name:PFIZER, S.A.
    Full Title: ENSAYO ALEATORIZADO, ABIERTO, EN FASE 3 DE ERLOTINIB SOLO O EN COMBINACION CON CP-751,871 EN PACIENTES CON CANCER DE PULMON NO MICROCITICO AVANZADO DE HISTOLOGIA NO ADENOCARCINOMATOSA.
    Medical condition: CPNM avanzado de histología no adenocarcinomatosa.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10025055 Lung cancer non-small cell stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) SI (Completed) IE (Completed) GB (Completed) BE (Completed) IT (Prematurely Ended) LV (Completed) FR (Completed) BG (Completed) HU (Completed) CZ (Prematurely Ended) GR (Completed)
    Trial results: View results
    EudraCT Number: 2010-021082-74 Sponsor Protocol Number: U31287-A-U201 Start Date*: 2011-01-21
    Sponsor Name:DAIICHI SANKYO DEVELOPMENT LTD.
    Full Title: RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND PHASE 1B/2 STUDY OF U3-1287 (AMG 888) IN COMBINATION WITH ERLOTINIB IN EGFR TREATMENT NAÏVE SUBJECTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WH...
    Medical condition: Treatment for advanced or metastatic NSCLC in combination with erlotinib in subjects who are epidermal growth factor receptor (EGFR) treatment naïve after failure of at least one prior chemotherapy...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029521 Non-small cell lung cancer stage IIIB PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) LT (Completed) HU (Completed) GB (Completed) BG (Completed) AT (Completed) SI (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-004854-12 Sponsor Protocol Number: N19RER Start Date*: 2019-04-12
    Sponsor Name:Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis
    Full Title: An Open-label Single-arm Pharmacokinetic Trial, Investigating the Effect of CYP3A4 inhibitor Ritonavir on the Pharmacokinetics of Erlotinib
    Medical condition: Advanced EGFR mutation positive non small cell lung cancer, pancreatic carcinoma, colorectal cancer and biliary cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-003998-34 Sponsor Protocol Number: CEGF816A2302 Start Date*: 2018-06-15
    Sponsor Name:Novartis Pharma AG
    Full Title: A Randomized, Open-label, Phase III Study of single agent Nazartinib Versus Investigator’s choice (Erlotinib or Gefitinib) as First-Line Treatment in Patients with locally advanced or metastatic No...
    Medical condition: Advanced Non-Small Cell Lung Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-004782-41 Sponsor Protocol Number: MO18660 Start Date*: 2006-08-16
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A parallel phase II study of Tarceva® (Erlotinib) in patients with advanced non-small cell lung cancer (Stage IIIB/IV) not pre-treated by chemotherapy including dose escalation to toxicity in curre...
    Medical condition: Patients with advanced NSCLC not previously treated with chemotherapy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) DE (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-004903-20 Sponsor Protocol Number: ABR-38376 Start Date*: 2012-05-09
    Sponsor Name:
    Full Title: Hydroxychloroquine as an anti-autophagy and chromatin modulating drug in combination with erlotinib in non-small cell lung cancer (NSCLC) patients: a single-center single arm open-label phase II trial
    Medical condition: Patients with histologically confirmed stage IV non-squamous non-small-cell lung cancer (NSCLC) • with an activating EGFR mutation who progressed on erlotinib or gefitinib monotherapy. OR • who...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-003814-14 Sponsor Protocol Number: ML19498 Start Date*: 2006-03-13
    Sponsor Name:Unidad Integral de Investigación en Oncología, S.L.
    Full Title: Pharmacodynamic study of Erlotinib (Tarceva) in patients with mestastatic or locally advanced Epidermoid carcinoma of the head and neck
    Medical condition: Mestastatic or locally advanced Epidermoid carcinoma of the head and neck
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-001762-85 Sponsor Protocol Number: NO21746 Start Date*: 2008-10-14
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: An open label study to determine the effect of R1507 (RO4858696) plus Tarceva (erlotinib) on progression-free survival in patients with stage IIIB/IV non-small cell lung cancer with progressive dis...
    Medical condition: To investigate whether R1507 can induce responses in patients with advanced NSCLC who have developed resistance to to erlotinib therapy and determine if clinical benefit can be obtained by adding R...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029521 Non-small cell lung cancer stage IIIB LLT
    9.1 10029522 Non-small cell lung cancer stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: Removed from public view
    EudraCT Number: 2011-005471-17 Sponsor Protocol Number: RASH Start Date*: 2012-05-08
    Sponsor Name:Klinikum der Universität München-Großhadern
    Full Title: Phase II Study for the Evaluation of the Efficacy of Gemcitabine plus Erlotinib in Rash-positive Patients with metastatic pancreatic cancer and good risk factors
    Medical condition: metastatic pancreatic carcinoma
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10033576 Pancreas carcinoma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-002854-78 Sponsor Protocol Number: BO17706 Start Date*: 2005-05-23
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: A randomised, double blind, placebo controlled, multicentre phase III trial to evaluate the efficacy and safety of adding bevacizumab to gemcitabine and erlotinib in patients with metastatic pancre...
    Medical condition: Metastatic pancreatic cancer (adenocarcinoma)
    Disease: Version SOC Term Classification Code Term Level
    PT 10033610 7.1
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed) FI (Completed) GB (Completed) SE (Completed) CZ (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-001973-10 Sponsor Protocol Number: SAT2-05-07 Start Date*: 2007-01-08
    Sponsor Name:GPC Biotech AG
    Full Title: A Phase 2 study comparing sequential satraplatin and erlotinib to single-agent erlotinib in patients >/= 70 years of age with unresectable stage 3 or 4 non-small cell lung cancer as 1st -line therapy
    Medical condition: Patients of at least 70 Years of Age with unresectable Stage 3 or 4 Non-Small Cell Lung Cancer. For further explanation see Inclusion (E.3) / Exclusion Criteria (E.4).
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: NL (Completed) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-000259-16 Sponsor Protocol Number: D4200C000057 Start Date*: 2006-10-02
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase III, Randomised, Double-Blind, Multi-Centre Parallel-Group Study to Assess the Efficacy of ZD6474 (ZACTIMA™ ) Versus Erlotinib (TARCEVA®) in Patients With Locally Advanced or Metastatic (St...
    Medical condition: Non-small cell lung cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DK (Completed) NO (Completed) ES (Completed) DE (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-022656-22 Sponsor Protocol Number: A7471009 Start Date*: 2011-09-13
    Sponsor Name:Pfizer, S.L.U.
    Full Title: A randomized double blind phase 3 efficacy and safety study of PF-00299804 versus erlotinib for the treatment of advanced non-small cell lung cancer following progression after, or intolerance to, ...
    Medical condition: Non-small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) SE (Completed) SK (Completed) PL (Completed) HU (Completed) IE (Completed) FI (Completed) BE (Completed) GB (Completed) DE (Completed) AT (Completed) DK (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2012-005476-33 Sponsor Protocol Number: I4C-MC-JTBB Start Date*: 2013-08-27
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized, Controlled Phase 2 Study Evaluating LY2875358 plus Erlotinib versus Erlotinib as First-Line Treatment in Metastatic Non–Small Cell Lung Cancer Patients with Activating EGFR Mutations ...
    Medical condition: Non-Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) GB (GB - no longer in EU/EEA) NL (Ongoing) IT (Completed) FR (Completed) ES (Ongoing) DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-004604-36 Sponsor Protocol Number: GGCP023/05 - ML19497 Start Date*: 2006-01-24
    Sponsor Name:Grupo Gallego de Cáncer de Pulmón (GGCP)
    Full Title: Ensayo clínico fase II, abierto, no aleatorizado, de erlotinib (Tarceva®) como tratamiento de mantenimiento en pacientes con cáncer de pulmón no microcítico en estadio III tras tratamiento con quim...
    Medical condition: tratamiento de mantenimiento en carcinoma no microcítico de pulmón en estadio III tras tratamiento con quimioterapia y radioterapia Maintenance therapy in NSCLC stage III following combined treatm...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-002069-36 Sponsor Protocol Number: 5189 Start Date*: 2013-02-06
    Sponsor Name:Hôpitaux Universitaires de Strasbourg
    Full Title: Randomized controlled clinical trial investigating Erlotinib for the treatment of chronic hepatitis C virus infection
    Medical condition: C hepatitis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10019805 - Hepatobiliary disorders 10019755 Hepatitis chronic active PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-001197-24 Sponsor Protocol Number: D791AC00011 Start Date*: 2006-09-18
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase II, Double-blind, Randomised, Parallel Group, Multi-centre Study Comparing gefitinib 250 mg (IRESSA™) with erlotinib 150 mg (Tarceva®) in Previously Treated Patients with Locally Advanced o...
    Medical condition: Non-small Cell Lung Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) AT (Completed) DE (Completed) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2007-003738-40 Sponsor Protocol Number: BO21129 Start Date*: 2008-08-07
    Sponsor Name:ROCHE
    Full Title: A phase II Biomarker Identification Trial for Erlotinib (Tarceva) in Patients with Advanced Pancreatic Carcinoma.
    Medical condition: Advanced Pancreatic carcinoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033633 Pancreatic neoplasms malignant (excl islet cell and carcinoid) HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) GB (Completed) LV (Completed) DE (Completed) LT (Completed) BG (Completed) SI (Completed)
    Trial results: View results
    EudraCT Number: 2007-004634-17 Sponsor Protocol Number: ARQ 197-209 Start Date*: 2008-07-09
    Sponsor Name:ArQule Inc.
    Full Title: A Randomized Phase 2 Study of Erlotinib plus ARQ 197 versus Erlotinib plus Placebo in Previously Treated Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer
    Medical condition: Non-Small Cell Lung Cancer (phase 3b/4)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029521 Non-small cell lung cancer stage IIIB LLT
    9.1 10029522 Non-small cell lung cancer stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) LV (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Aug 02 09:07:30 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA